Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.
Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA ...
With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...
The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, COPD exacerbation history groups were “mediocre” in ...
Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.
Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...
China: A recent multicenter randomized controlled trial has highlighted the potential benefits of acupuncture as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback